Rahul A Nathwani1, S Ram Kumar, Telfer B Reynolds, Neil Kaplowitz. 1. Division of Gastrointestinal and Liver Disease, Department of Medicine, Keck School of Medicine/University of California-Los Angeles, 2011 Zonal Avenue, HMR#101, Los Angeles, CA 90033, USA.
Abstract
BACKGROUND: Choledocholithiasis causes elevations in levels of alkaline phosphatase out of proportion to aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Isolated marked elevation in AST and ALT levels over 1,000 IU/L has been reported infrequently in patients with choledocholithiasis. METHODS: The charts of 18 patients who presented between 1971 and 2002 with documented choledocholithiasis and AST or ALT levels greater than 1,000 IU/L were retrospectively reviewed. An extensive work-up for coexisting disease processes to account for the abnormal AST and ALT levels was negative. RESULTS: Eighteen patients (16 women, 16 Hispanics, age 38 +/- 3 yr) presented with symptoms of choledocholithiasis and marked transaminase elevation. Peak levels of AST and ALT were 1,062 +/- 129 and 1,119 +/- 90, respectively. Following successful management of gallstone disease, AST and ALT levels fell rapidly to 129 +/- 22 and 268 +/- 61, respectively, within 3-14 days. There was also a concomitant improvement in the levels of bilirubin and alkaline phosphatase. CONCLUSIONS: In the absence of other hepatobiliary or pancreatic disease, choledocholithiasis can result in elevations in AST and/or ALT greater than 1,000 IU/L. These levels fall markedly once the gallstone disease is appropriately managed.
BACKGROUND:Choledocholithiasis causes elevations in levels of alkaline phosphatase out of proportion to aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Isolated marked elevation in AST and ALT levels over 1,000 IU/L has been reported infrequently in patients with choledocholithiasis. METHODS: The charts of 18 patients who presented between 1971 and 2002 with documented choledocholithiasis and AST or ALT levels greater than 1,000 IU/L were retrospectively reviewed. An extensive work-up for coexisting disease processes to account for the abnormal AST and ALT levels was negative. RESULTS: Eighteen patients (16 women, 16 Hispanics, age 38 +/- 3 yr) presented with symptoms of choledocholithiasis and marked transaminase elevation. Peak levels of AST and ALT were 1,062 +/- 129 and 1,119 +/- 90, respectively. Following successful management of gallstone disease, AST and ALT levels fell rapidly to 129 +/- 22 and 268 +/- 61, respectively, within 3-14 days. There was also a concomitant improvement in the levels of bilirubin and alkaline phosphatase. CONCLUSIONS: In the absence of other hepatobiliary or pancreatic disease, choledocholithiasis can result in elevations in AST and/or ALT greater than 1,000 IU/L. These levels fall markedly once the gallstone disease is appropriately managed.
Authors: Andrew Stolz; Victor Navarro; Paul H Hayashi; Robert J Fontana; Huiman X Barnhart; Jiezhun Gu; Naga P Chalasani; Maricruz M Vega; Herbert L Bonkovsky; Leonard B Seeff; Jose Serrano; Bharathi Avula; Ikhlas A Khan; Elizabeth T Cirulli; David E Kleiner; Jay H Hoofnagle Journal: Aliment Pharmacol Ther Date: 2019-04-01 Impact factor: 8.171
Authors: Eula Plana Tetangco; Natasha Shah; Hafiz Muhammad Sharjeel Arshad; Hareth Raddawi Journal: J Investig Med High Impact Case Rep Date: 2016-05-18
Authors: Brooks D Cash; Brian E Lacy; Philip S Schoenfeld; Leonard S Dove; Paul S Covington Journal: Am J Gastroenterol Date: 2016-12-06 Impact factor: 10.864